Novel therapeutic options for Waldenstrms macroglobulinemia

The therapeutic potential for Waldenstrms macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this disease. In this interview at the 1st European ... Author: VJHemOnc Added: 07/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

CONCLUSIONS: JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy. PMID: 31432632 [PubMed - in process]
Source: Annals of Laboratory Medicine - Category: Laboratory Medicine Tags: Ann Lab Med Source Type: research
Condition:   Waldenstrom Macroglobulinemia Interventions:   Drug: Ibrutinib;   Drug: Rituximab Sponsor:   Janssen Pharmaceutical K.K. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
X-linked agammaglobulinemia (XLA), caused by a mutation in the Bruton’s tyrosine kinase (BTK) gene, is rarely reported in patients with recurrent hemophagocytic lymphohistiocytosis (HLH). This mutation leads to significantly reduced numbers of circulatory B cells and serum immunoglobulins in patients. Therefore, they exhibit repetitive bacterial infections since infancy, and immunoglobulin (Ig) replacement therapy is the primary treatment. HLH is a life-threatening condition with manifestations of nonremitting fever, hepatosplenomegaly, cytopenias, coagulopathy, lipid disorder, and multiple organ failure. It is cause...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
Condition:   Waldenstrom Macroglobulinemia Interventions:   Drug: Dexamethasone, cyclophosphamide, rituximab;   Drug: Rituximab, ibrutinib Sponsors:   University College, London;   Janssen-Cilag Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mantle Cell Lymphoma;   Waldenström Macroglobulinemia Intervention:   Drug: Zanubrutinib Sponsor:   BeiGene Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Genetics | Macroglobulinemia | Waldenstrom's Macroglobulinemia